NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NOVAVAX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.82−0.44 (-3.91%)
Close on Oct 19, 2026
- Market cap
- $1.78B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.72 (+33.58%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
NOVAVAX INC saw revenue fall 61.6% to $413.80M over the twelve months to Jun 30, 2026. Operating income fell 166.6% to -$234.12M, moving the operating margin from 32.6% to -56.6%.
Revenue
$413.80M
-61.6% vs. a year earlier
Operating income
-$234.12M
-166.6% vs. a year earlier
EPS, diluted
-$1.54
-167.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.78B
- P/E ratio
- –
- Price to sales
- 4.30
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $413.80M
- Net income
- -$247.73M
- EPS, diluted
- -$1.54
- Book value per share
- -$1.16
- Diluted shares
- 165M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$413.80M-61.6% YoY
Gross profit
$325.26M-65.8% YoY
Operating income
-$234.12M-166.6% YoY
Net income
-$247.73M-158.6% YoY
EPS, diluted
-$1.54-167.5% YoY
Free cash flow
–
Reported periodTrailing twelve months